122 related articles for article (PubMed ID: 18021687)
21. [18F-FDG imaging by coincidence circuit SPECT with low-dose CT in preoperative assessment of pulmonary lesions].
Wang Q; Huang LL; Yue MG; Qin SL; Wang Y; Nie YX; Zhang CQ; Liang TJ; Zhao YM
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):924-7. PubMed ID: 17533745
[TBL] [Abstract][Full Text] [Related]
22. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling.
Steinert HC; Hauser M; Allemann F; Engel H; Berthold T; von Schulthess GK; Weder W
Radiology; 1997 Feb; 202(2):441-6. PubMed ID: 9015071
[TBL] [Abstract][Full Text] [Related]
23. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
[TBL] [Abstract][Full Text] [Related]
24. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy.
Eschmann SM; Friedel G; Paulsen F; Budach W; Harer-Mouline C; Dohmen BM; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):804-8. PubMed ID: 12029555
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of bone scintigraphy and (18)F-FDG PET/CT in bone metastases of lung cancer patients].
Portilla-Quattrociocchi H; Banzo I; Martínez-Rodríguez I; Quirce R; Jiménez-Bonilla J; de Arcocha Torres M; Medina-Quiroz P; del Castillo R; Rubio-Vassallo A; Carril JM
Rev Esp Med Nucl; 2011; 30(1):2-7. PubMed ID: 21208693
[TBL] [Abstract][Full Text] [Related]
26. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
[TBL] [Abstract][Full Text] [Related]
27. Incidence of Brain Metastases on Follow-up
Nia ES; Garland LL; Eshghi N; Nia BB; Avery RJ; Kuo PH
J Nucl Med Technol; 2017 Sep; 45(3):193-197. PubMed ID: 28705927
[TBL] [Abstract][Full Text] [Related]
28. [Clinical value of computed tomography and fluorine-18 fluorodeoxyglucose positron remission tomography in diagnosis of mediastinal metastasis of non small cell lung cancer].
Zhi XY; Liu BD; Xu QS; Zhang Y; Su L; Wang HR; Hu M
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2026-9. PubMed ID: 16313793
[TBL] [Abstract][Full Text] [Related]
29. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET.
Hara T; Inagaki K; Kosaka N; Morita T
J Nucl Med; 2000 Sep; 41(9):1507-13. PubMed ID: 10994730
[TBL] [Abstract][Full Text] [Related]
30. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of (18)F-FDG PET-CT for differentiation of pulmonary pathology in an approach of outpatient fast track assessment.
Aukema TS; Valdés Olmos RA; Klomp HM; Teertstra HJ; Belderbos JS; Vogel WV; Baas P; Burgers SA; van den Heuvel MM
J Thorac Oncol; 2009 Oct; 4(10):1226-30. PubMed ID: 19687763
[TBL] [Abstract][Full Text] [Related]
32. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
[TBL] [Abstract][Full Text] [Related]
33. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG.
Bruzzi JF; Truong MT; Marom EM; Mawlawi O; Podoloff DA; Macapinlac HA; Munden RF
AJR Am J Roentgenol; 2006 Oct; 187(4):1116-23. PubMed ID: 16985164
[TBL] [Abstract][Full Text] [Related]
34. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
35. Additional value of FDG-PET to contrast enhanced-computed tomography (CT) for the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Japanese multicenter clinical study.
Kubota K; Murakami K; Inoue T; Itoh H; Saga T; Shiomi S; Hatazawa J
Ann Nucl Med; 2011 Dec; 25(10):777-86. PubMed ID: 21901365
[TBL] [Abstract][Full Text] [Related]
36. Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.
Chaft JE; Dunphy M; Naidoo J; Travis WD; Hellmann M; Woo K; Downey R; Rusch V; Ginsberg MS; Azzoli CG; Kris MG
J Thorac Oncol; 2016 Apr; 11(4):537-44. PubMed ID: 26724474
[TBL] [Abstract][Full Text] [Related]
37. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
[TBL] [Abstract][Full Text] [Related]
38. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
Farrell MA; McAdams HP; Herndon JE; Patz EF
Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
[TBL] [Abstract][Full Text] [Related]
39. Nonpalpable supraclavicular lymph nodes in lung cancer patients: preoperative characterization with 18F-FDG PET/CT.
Sung YM; Lee KS; Kim BT; Kim S; Kwon OJ; Choi JY; Yang SO
AJR Am J Roentgenol; 2008 Jan; 190(1):246-52. PubMed ID: 18094319
[TBL] [Abstract][Full Text] [Related]
40. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
